Last update 25 May 2025

BIIB-023

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-TWEAK monoclonal antibody, BIIB 023
Target
Action
inhibitors
Mechanism
TWEAK inhibitors(Tumor necrosis factor ligand superfamily member 12 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lupus NephritisPhase 2
United States
01 Jul 2012
Lupus NephritisPhase 2
Argentina
01 Jul 2012
Lupus NephritisPhase 2
Australia
01 Jul 2012
Lupus NephritisPhase 2
Belgium
01 Jul 2012
Lupus NephritisPhase 2
Brazil
01 Jul 2012
Lupus NephritisPhase 2
Colombia
01 Jul 2012
Lupus NephritisPhase 2
France
01 Jul 2012
Lupus NephritisPhase 2
Germany
01 Jul 2012
Lupus NephritisPhase 2
Hong Kong
01 Jul 2012
Lupus NephritisPhase 2
Hungary
01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
87
Placebo+BIIB023
(Placebo (211LE201) to BIIB023 3 mg/kg (211LE202))
dhxbxkykrv = xqwaulftcn yzbkfjmejx (qrluiktqdy, soonugngia - dmbwxnmzbk)
-
18 Jan 2017
211LE202+BIIB023
(BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202))
dhxbxkykrv = wummsyxmjf yzbkfjmejx (qrluiktqdy, rptspobtdr - jburbvqqet)
Phase 2
276
oral corticosteroids+mycophenolate mofetil
(Placebo)
rqyhlujmfl = jyoqbtbfde nhdbsfvnso (dmtssmlqbc, vatrjcfefm - bkejhsgdew)
-
18 Jan 2017
oral corticosteroids+BIIB023+mycophenolate mofetil
(BIIB023 3 mg/kg)
rqyhlujmfl = cdwimcvxmh nhdbsfvnso (dmtssmlqbc, lxupzoiyym - pauivavlwk)
Phase 2
Lupus Nephritis
TWEAK | Fn14
188
yfplyqjqfp(gqtjklprkw) = 11% and 17% of placebo and BIIB023-treated patients, respectively ldwhydvnji (irfnvxexof )
Negative
15 Nov 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free